On the 18th of February 2022 the Swedish investment company Nordstjernan signed the agreement to acquire Aidian Oy and it will be effective on 31st of March, 2022. Kindly see the press release:
"We are very excited to get Nordstjernan as our new shareholder and consider this as a great opportunity for a long term partnership as well as a great opportunity for Aidian to strengthen our growth strategy", says Aidian’s CEO Juho Himberg. Nordstjernan is an active owner with long-term commitment to their companies and they are very experienced in the health care market.
Nordstjernan was founded by the Ax:son Johnson family in 1890. They are based in Sweden, Stockholm. For more than 130 years, they have owned and developed competitive companies. Overall, Nordstjernan’s holdings generate sales in excess of SEK 100 billion and have some 50,000 employees.
Aidian will continue its businesses as before, providing high quality and efficient solutions for the in vitro diagnostic health care market. The acquisition does not require any actions by our partners, our business relation will continue as before. For the sake of clarity, our name, Aidian Oy, and our business identity number 1855216-1 will remain the same.
"We are thanking our partners for the continuous efforts and invite you all to continue growing the businesses together with Aidian, and keep up the level of customer services and product quality that Aidian is very proud of!", concludes Himberg
For more information
Aidian Oy, former Orion Diagnostica Oy, is a Finnish based IVD company that has close to 50 years of experience in developing and manufacturing reliable, fast and easy to use diagnostic tests especially for primary care and clinical laboratories. Aidian’s global presence covers over 70 countries. Aidian is headquartered in Espoo, Finland.